Systemic levels of MMP2/TIMP2 and cardiovascular risk in CAPD patients

Nephron - Clinical Practice

Volumn 115, Issue 4, 2010, Pages

  Pawlak, Krystyna ^a   Tankiewicz, Janina ^a   Mysliwiec, Michal ^a   Pawlak, Dariusz ^a,b  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b UNIVERSITY OF WARMIA AND MAZURY IN OLSZTYN   (Poland)

Author keywords

Continuous ambulatory peritoneal dialysis; Metalloproteinases; Quinolinic acid; Tissue inhibitors of metalloproteinases

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; COPPER ZINC SUPEROXIDE DISMUTASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; GELATINASE A; GELATINASE B; KYNURENINE; NITRATE; QUINOLINIC ACID; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; ANEMIA; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL;

ADULT; BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 77951217221     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000313483     Document Type: Article

References (29)

1. Prichard S: Cardiovascular risk in peritoneal dialysis. Contrib Nephrol. Basel, Karger, 2003, vol 140, pp 82-90.
2. Vincenti MP: The matrix metalloproteinase and tissue inhibitor of metalloproteinase genes. Transcriptional and posttranscriptional regulation, signal transduction and cell-type-specific expression. Methods Mol Biol 2001; 151: 121-148.
3. Pasterkamp G, Schoneveld AH, Hijnen DJ, de Kleijn DPV, Teepen H, van der Wal AC, Borst C: Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery. Atherosclerosis 2000; 150: 245-253.
4. Zaltsman AB, George SJ, Newby AC: Increased secretion of tissue inhibitors of metalloproteinases 1 and 2 from the aortas of cholesterol fed rabbits partially counterbalances increased metalloproteinase activity. Arterioscler Thromb Vasc Biol 1997; 19: 1700-1707.
5. Zeng B, Prasan A, Fung KC, Solanki V, Bruce D, Freedman SB, Brieger D: Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease. Intern Med J 2005; 35: 331-335.
6. Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuwahara F, Ueno T, Sugi K, Imaizumi T: Peripheral blood levels of matrix metalloproteinases-2 and -9 are elevated in patients in acute coronary syndromes. J Am Coll Cardiol 1998; 32: 368-372.
7. Silacci P, Hayoz D: Oxidative stress as the triggering event for vascular remodeling. Nephrol Dial Transplant 1998; 13: 1343-1346.
8. Pawlak K, Pawlak D, Mysliwiec M: Serum matrix metalloproteinase-2 and increased oxidative stress are associated with carotid atherosclerosis in hemodialyzed patients. Atherosclerosis 2007; 190: 199-204.
9. Schroecksnadel K, Frick B, Winkler C, Fusch D: Crucial role of interferon-γ and stimulated macrophages in cardiovascular disease. Curr Vasc Pharmacol 2006; 4: 205-213.
10. Stone TW, Darlington LG: Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov 2002; 1: 609-620.
11. Pawlak D, Tankiewicz A, Matys T, Buczko W: Peripheral distribution of kynurenine metabolites and activity of kynurenine pathway enzymes in renal failure. J Physiol Pharmacol 2003; 54: 175-189.
12. Pawlak D, Koda M, Pawlak S, Wolczynski S, Buczko W: Contribution of quinolinic acid in the development of anemia in renal insufficiency. Am J Physiol Renal Physiol 2003; 284:F693-F700.
13. Pawlak D, Pawlak K, Malyszko J, Mysliwiec M, Buczko W: Accumulation of toxic products degradation of kynurenine in hemodialyzed patients. Int Urol Nephrol 2001; 33: 399-404.
14. Saito K, Fujigaki S, Heyes MP, Shibata K, Takemura M, Fujii H, Wada H, Noma A, Seishima M: Mechanism of increases in L - kynurenine and quinolinic acid in renal insufficiency. Am J Physiol Renal Physiol 2000; 279:F565-F572.
15. Schefold JC, Zeden J-P, Fotopoulou C, von Haehling S, Pschowski R, Hasper D, Volk HD, Schuett Ch, Reinke P: Increased indoleamine 2,3-dioxygenase activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms. Nephrol Dial Transplant 2009; 24: 1901-1908.
16. Pawlak K, Brzosko S, Mysliwiec M, Pawlak D: Kynurenine, quinolinic acid - the new factors linked to carotid atherosclerosis in patients with end-stage renal disease. Atherosclerosis 2009; 204: 561-566.
17. Santamaria A, Flores-Escartin A, Martinez JC, Osorio L, Galvan-Arzate S, Chaverri JP, Maldonado PD, Medina-Campos ON, Jimenez- Capdeville ME, Manjarrez J, Rios C: Copper blocks quinolinic acid neurotoxicity in rats: contribution of antioxidant systems. Free Radic Biol Med 2003; 35: 418-427.
18. Santamaria A, Salvatierra-Sanches R, Vazquez-Roman B, Santiago-Lopez D, Villeda- Hernandez J, Galvan-Arzate S, Jimenez- Capdeville ME, Ali SF: Protective effects of the antioxidant selenium on quinolinic acidinduced neurotoxicity in rats: in vitro and in vivo studies. J Neurochem 2003; 86: 479-488.
19. Preston GA, Barrett CV, Alcotra DA, Hogan SL, Dinwiddie L, Jennette JC, Falk RJ: Serum matrix metalloproteinases MMP-2 and MMP-3 levels in dialysis patients vary independently of CRP and IL-6 levels. Nephron 2002; 92: 817-823.
20. Ebihara I, Nakamura T, Tomino Y, Shimada N, Koide H: Metalloproteinase-9 mRNA expression in monocytes from patients with chronic renal failure. Am J Nephrol 1998; 18: 305-310.
21. Chang H-R, Yang S-F, Li M-L, Lin C-C, Hsieh Y-S, Lian J-D: Relationship between circulating matrix metalloproteinase-2 and -9 and renal function in patients with chronic kidney disease. Clin Chim Acta 2006; 366: 243-248.
22. Marshall BC, Santana A, Xu OP, Petersen MJ, Campbell EJ, Hoidal JR: Metalloproteinases and tissue inhibitors of metalloproteinases in mesothelial cells. J Clin Invest 1993; 91: 1792-1799.
23. Nagano M, Fukami K, Yamagishi S-I, Ueda S, Kaida Y, Matsumoto T, Yoshimura J, Hazama T, Takamiya Y, Kusumoto T, Gohara S, Tanaka H, Adachi H, Okuda S: Circulating matrix metalloproteinase-2 is an independent correlate of proteinuria in patients with chronic kidney disease. Am J Nephrol 2009; 29: 109-115.
24. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C: Oxidative stress in end-stage renal disease: an emerging treat to patient outcome. Nephrol Dial Transplant 2003; 18: 1272-1280.
25. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS: Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest 1996; 98: 2572-2579.
26. Inoue N, Takeshita S, Gao D, Ishida T, Kawashima S, Akita H, Tawa R, Sakurai H, Yokoyama M: Lysophosphatidylcholine increases the secretion of matrix metalloproteinase-2 through the activation of NADH/NADPH oxidase in cultured aortic endothelial cells. Atherosclerosis 2001; 155: 45-52.
27. Nagase H: Activation mechanisms of matrix metalloproteinases. Biol Chem 1997; 378: 151-160.
28. Rezaei A, Ardestani SK, Forouzandeh M, Tavanger SM, Khorramizadeh MR, Payabvash S, Nezami BG, Jahanshiri Z, Tavakoli Z, Shariftabrizi A, Dehpour AR: The effects of N-acetylcysteine on the expression of matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 in hepatic fibrosis in bile duct ligated rats. Hepatol Res 2008; 38: 1252-1263.
29. Galis ZS, Sukhova GK, Lark MW, Libby P: Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94: 2493-2503.